These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 38399561)

  • 1. Refractory IgA Nephropathy: A Challenge for Future Nephrologists.
    Di Leo V; Annese F; Papadia F; Russo MS; Giliberti M; Sallustio F; Gesualdo L
    Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive agents for treating IgA nephropathy.
    Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive agents for treating IgA nephropathy.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children.
    Vaz de Castro PAS; Bitencourt L; Pereira BWS; Lima AQR; Hermida HS; Moreira Neto CR; Mestriner MD; Simões E Silva AC
    Pediatr Nephrol; 2022 Mar; 37(3):499-508. PubMed ID: 34686915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy.
    Dillon JJ
    Semin Nephrol; 2004 May; 24(3):218-24. PubMed ID: 15156527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-immunosuppressive treatment for IgA nephropathy.
    Reid S; Cawthon PM; Craig JC; Samuels JA; Molony DA; Strippoli GF
    Cochrane Database Syst Rev; 2011 Mar; (3):CD003962. PubMed ID: 21412884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
    Eitner F; Ackermann D; Hilgers RD; Floege J
    J Nephrol; 2008; 21(3):284-9. PubMed ID: 18587715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy.
    Trachtman H; Komers R; Inrig J
    Expert Rev Clin Immunol; 2024 Jun; 20(6):571-576. PubMed ID: 38362830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Management of IgA nephropathy].
    Amoroso L; De Sanctis L; Cappelli P; Di Vito R; Sirolli V; Bonomini M
    G Ital Nefrol; 2011; 28(6):622-32. PubMed ID: 22167613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
    Li X; Liu Y; Lv J; Shi S; Liu L; Chen Y; Zhang H
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy.
    Zhang Q; Shi SF; Zhu L; Lv JC; Liu LJ; Chen YQ; Zhang H; Wang HY
    Am J Nephrol; 2012; 35(4):312-20. PubMed ID: 22456060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker therapy for IgA nephropathy: A meta-analysis of randomized controlled trials.
    Ji Y; Yang K; Xiao B; Lin J; Zhao Q; Bhuva MS; Yang H
    J Cell Biochem; 2019 Mar; 120(3):3689-3695. PubMed ID: 30270542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine.
    Pozzi C; Andrulli S; Pani A; Scaini P; Roccatello D; Fogazzi G; Pecchini P; Rustichelli R; Finocchiaro P; Del Vecchio L; Locatelli F
    J Nephrol; 2013; 26(1):86-93. PubMed ID: 22460183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Multicenter investigation of therapeutic status of children with IgA nephropathy in China].
    Working Group for National Survey on Status of Diagnosis and Treatment of Childhood Renal Diseases
    Zhonghua Er Ke Za Zhi; 2013 Jul; 51(7):486-90. PubMed ID: 24267127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function.
    Moriyama T; Amamiya N; Ochi A; Tsuruta Y; Shimizu A; Kojima C; Itabashi M; Takei T; Uchida K; Nitta K
    Clin Exp Nephrol; 2011 Oct; 15(5):700-707. PubMed ID: 21625892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of inhibitors of renin-angiotensin-aldosterone system (RAS) and combination therapy of steroids plus RAS inhibitors for patients with advanced immunoglobulin A nephropathy and impaired renal function.
    Moriyama T; Nakayama K; Ochi A; Amemiya N; Tsuruta Y; Kojima C; Itabashi M; Takei T; Uchida K; Nitta K
    Clin Exp Nephrol; 2012 Apr; 16(2):231-7. PubMed ID: 22038185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients.
    Zhang L; Zeng X; Fu P; Wu HM
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009120. PubMed ID: 24953826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN)].
    Nagy J; Sági B; Máté J; Vas T; Kovács T
    Orv Hetil; 2017 Dec; 158(49):1946-1952. PubMed ID: 29199436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis.
    Cheng J; Zhang X; Tian J; Li Q; Chen J
    Int J Clin Pract; 2012 Oct; 66(10):917-23. PubMed ID: 22994326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy.
    Tanaka S; Ninomiya T; Katafuchi R; Masutani K; Nagata M; Tsuchimoto A; Hirakata H; Kitazono T; Tsuruya K
    Clin Exp Nephrol; 2016 Oct; 20(5):689-698. PubMed ID: 26564155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.